

From: Liverpool-ECMC
Sent: 04 September 2019 14:44
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter September 2019 - Haematology

LIVERPOOL ECMC NEWSLETTER SEPTEMBER 2019 *HAEMATOLOGY*




GILEAD IMMUNO-ONCOLOGY MEDICAL EDUCATION PROGRAMME ROADSHOW: CAR-T

Dr Nagesh Kalakonda will be speaking at the Gilead Immuno-Oncology Medical Education event due to take place on the 12th and 13th September 2019. The programme focusses on CAR-T cell therapy. Further details can be found here:

<https://eu.eventscloud.com/ehome/gileadaction2019man/Programme/>

HYST WORKSHOP



We would like to invite you to a workshop to discuss the HYST study on Thursday 10th October in the University of Liverpool. The HYST study is a

mechanistic investigation into drug and chemical induced hypersensitivity reactions with current research focussed on immune-related adverse events.

This workshop will be a great opportunity to hear about the latest research developments linked to the HYST study and discuss potential clinical and translational collaborations. To find out more information or to register your attendance please email: livecmc@liv.ac.uk. A complete agenda will be circulated soon.



UK REPRODUCIBILITY NETWORK (UKRN)

The Liverpool ECMC supports the objectives of the UK Reproducibility Network (UKRN) and the local network in Liverpool. Further details on the UKRN can be found on the website:

<https://www.bristol.ac.uk/psychology/research/ukrn/>

Professor Bill Greenhalf (Molecular and Clinical Cancer Medicine) leads the University of Liverpool Network. The network includes active contribution from Professor Ben Ambridge, Dr Andrew Jones, Dr Charlotte Hardman, Dr Eric Robinson and Dr Colin Bannard (School of Psychology) and Professor Paula Williamson (Biostatistics).

OPEN TRIALS

Please contact **Jane Tinsley** for potential referral to these trials.



- Telephone: 0151 706 4886

- **AVAIL-T** – A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)

- **MANIFEST** – A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI0610 with and without Ruxolitinib in Patients with Myelofibrosis)
- **RomiCar** – Phase I/II study to determine the MTD and overall response rate of the combination of romidepsin and carfilzomib in relapsed / refractory peripheral T-cell lymphoma
- **TIDaL** – Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

Find out more...

EVENTS & JOB OPPORTUNITIES

EVENTS

- **11th International ICAPS Conference on "Cancer Prevention: Targeting Infection, Inflammation and the Immune System" (SEPTEMBER 2019)**
- **An introduction to CAR-T in the UK (SEPTEMBER 2019)**
- **New directions in Immuno-Oncology (SEPTEMBER 2019)**
- **HYST Workshop (OCTOBER 2019)**
- **Successful nursing in a Phase I environment (OCTOBER 2019)**
- **PSGBI Annual Network Meeting (NOVEMBER 2019)**
- **<https://www.ecmcnetwork.org.uk/events>**

JOB OPPORTUNITIES

- **GCP Laboratory Technician GRADE 5 (closing date: 04/09/2019)**

CONTACT US

If you require any information which isn't on the website please contact the Liverpool ECMC Team via [e-mail](#).

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk